ASCO 2024
Advertisement
Kai-Keen Shiu, MD, PhD, continues his discussion on neoadjuvant pembrolizumab for patients with colorectal cancer.
Dr. Shiu also discusses how the NEOPRISM-CRC study exceeded its primary endpoint with a high pCR rate.
Drs. Ebben and Uboha break down the importance of the QUIC study, a phase 2 investigation of first-line treatment of BTC.
Dr. Knox details the early results of the PASS-01 trial, which looked at PDAC signature stratification for treatment.
Richard Finn, MD, of University of California, Los Angeles, highlights 3-year follow-up data from KEYNOTE-966.
Dr. Galle shares the first results from CheckMate 9DW, a comparison of nivo/ipi against sorafenib or lenvatinib for uHCC.
CheckMate 9DW trial: Nivolumab plus ipilimumab improves overall survival in unresectable hepatocellular carcinoma
The trial compared mFOLFIRINOX vs gemcitabine/nab-paclitaxel in advanced PDAC.
Phase 3 IKF-575/RENAISSANCE trial shows surgery after FLOT may benefit RPLN-only metastatic gastric cancer patients.
Switch maintenance may extend the benefits of an initial treatment strategy and can delay clinical deterioration.
Drs. Filippo Pietrantonio and Nataliya Uboha continue their conversation with a review of the OS data from CodeBreaK 300.
Drs. Filippo Pietrantonio and Nataliya Uboha break down the results of the phase 3 ARMANI trial.
Dr. Schlechter also highlights how this research may effect long-term efficacy and durability of response in patients.
Dr. Schlechter discusses a phase 1 dose escalation study of a novel coupled CAR-T therapy for patients with mCRC.
Dr. Weinberg explains the mechanism of action for BXCL701 and how it synergizes with pembrolizumab.
Dr. Raghav discusses ctDNA as an early predictor of treatment response in colorectal cancer.
Treatment-related adverse events were mostly sitravatinib related and included hand-foot syndrome and hypertension.
The primary end point of the analysis was OS, and secondary end points included PFS and ORR.
The phase 3 trial examined the effects of TNT with LCRT and CAPOX on outcomes in high-risk locally advanced rectal cancer.
GABARNANCE compared the use of gemcitabine plus nab-paclitaxel with concurrent chemoradiotherapy with S-1.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.